02607 上海醫藥
按盘价 
12.680 +0.560 (+4.620%) 盈利能力分析
| 2023/12 | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| 资产回报率 (%) | 1.838% | 3.107% | 3.259% | 3.142% | 3.093% |
| 股东资金回报率 (%) | 5.558% | 9.650% | 10.755% | 10.334% | 10.117% |
| 资本运用回报率 (%) | 4.205% | 6.424% | 7.113% | 7.364% | 6.538% |
边际利润分析
| 2023/12 | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| 毛利率 (%) | -- | -- | -- | -- | -- |
| 未计利息、税项、折旧及摊销前利润率 (%) | 4.145% | 5.178% | 5.063% | 5.057% | 4.704% |
| 税前边际利润率 (%) | 2.710% | 3.797% | 3.773% | 3.739% | 3.357% |
| 纯利率 (%) | 1.448% | 2.421% | 2.360% | 2.343% | 2.187% |
变现能力分析
| 2023/12 | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| 流动比率 (X) | 1.327 X | 1.351 X | 1.269 X | 1.220 X | 1.315 X |
| 速动比率 (X) | 1.028 X | 1.039 X | 0.973 X | 0.947 X | 0.981 X |
财务杠杆分析
| 2023/12 | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| 总负债 / 总资产比率 (%) | 62.105% | 60.632% | 63.860% | 63.307% | 63.959% |
| 总债项 / 总资产比率 (%) | 24.489% | 22.511% | 24.941% | 24.619% | 25.261% |
| 净债项 / 总资产比率 (%) | 10.092% | 8.681% | 11.241% | 9.674% | 12.013% |
| 总债项 / 股东资金比率 (%) | 75.756% | 66.507% | 82.582% | 80.980% | 83.089% |
| 长期债项 / 股东资金比率 (%) | 10.706% | 11.275% | 17.407% | 5.920% | 24.700% |
| 净债项 / 股东资金比率 (%) | 31.220% | 25.648% | 37.220% | 31.820% | 39.515% |
| 净现金 / (债项) ($) | (213.93亿) | (172.00亿) | (183.72亿) | (144.32亿) | (164.61亿) |
| 每股净现金 / (债项) ($) | (5.777) | (4.652) | (6.464) | (5.078) | (5.792) |
| 总债项 / 资本运用比率 (%) | 57.936% | 51.006% | 56.921% | 60.158% | 55.455% |
| 利息盈利率 (X) | 4.742 X | 6.214 X | 6.364 X | 6.082 X | 5.457 X |
营运效率分析
| 2023/12 | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| 存货周转率日数 (日) | -- | -- | -- | -- | -- |
| 应收贸易帐周转率日数 (日) | 100.543日 | 100.655日 | 95.064日 | 95.716日 | 87.545日 |
| 应付贸易帐周转率日数 (日) | 74.458日 | 73.605日 | 67.468日 | 71.004日 | 70.146日 |
| 备注： | 实时报价更新时间为30/09/2024 17:59 |
| 港股实时基本市场行情由香港交易所提供; 香港交易所指定免费发放实时基本市场行情的网站。 | |
| 股东应占溢利/(亏损) (千) | RMB 2,941,911 |
| 增长率 | 12.725% |
| 每股盈利/(亏损) | RMB 0.790 |
| 每股账面资产净值 (¥) | RMB 18.898 |